TNF alpha inhibitors in Alzheimer’s disease: a systematic review

Justyna O. Ekert1, Rebecca L. Gould1, Gemma Reynolds2, Robert J. Howard1

(1) Division of Psychiatry, University College London, 149 Tottenham Court Rd, London, W1T 7NF, Telephone: 020 7679 9225  
(2) Dr Gemma Reynolds, Department of Psychology, Middlesex University, The Burroughs, London, NW4 4BT, Telephone: 020 8411 6506

Keywords: Alzheimer’s Disease, Tumor-necrosis factor alpha, Dementia

Word count: 4496

This article was submitted in partial fulfilment of the requirements for a degree in Neuroscience. This research was supported by University College London and Middlesex University. The authors declare that there are no conflicts of interest.

**Abstract**

OBJECTIVES  
The objective of this study was to evaluate the effect of tumor necrosis factor-alpha inhibitors (TNF-I) on Alzheimer’s disease (AD)-associated pathology.  
DESIGN  
A literature search of PubMed, Embase, PsychINFO, Web of Science, Scopus and the Cochrane Library databases for human and animal studies that evaluated the use of TNF-I was performed on 26th October 2016.   
RESULTS  
The main outcomes assessed were cognition and behaviour, reduction in brain tissue mass, presence of plaques and tangles, and synaptic function. Risk of bias was assessed regarding blinding, statistical model, outcome reporting and other biases. Sixteen studies were included, 13 of which were animal studies and 3 of which were human. All animal studies found that treatment with TNF-I leads to an improvement in cognition and behaviour. None of the studies measured change in brain tissue mass. The majority of studies documented a beneficial effect in other areas, including the presence of plaques and tangles and synaptic function. The amount of data from human studies was limited. Two out of 3 studies concluded that TNF-I are beneficial in AD patients, with one being an observational study and the latter being a small pilot study, with a high risk of bias.  
CONCLUSION  
It was concluded that a large scale randomised controlled trial assessing the effectiveness of TNF-I on humans is warranted.

INTRODUCTION

**The role of neuroinflammation in AD**

Almost three decades ago, McGeer and colleagues noted the association between anti-inflammatory drugs and reduced risk for developing Alzheimer's disease (AD) (McGeer, Rogers, McGeer & Sibley,1990). Subsequent studies led to identification of large numbers of immune cells found in the proximity of senile plaques and neurofibrillary tangles, the histological lesions characteristic for AD (Eldik et al. 2016).

The presence of A deposits in the brain can lead to the activation of an immune response and the recruitment of glial cells. In response to toxic A deposits, microglia undergo morphological and functional changes to neutralise them (Olabarria, Noristani, Verkhratsky & Rodriguez, 2010). As glial cells are unable to remove the debris, their function becomes altered in a way that they actively contribute to inflammation (Bronzuoli et al. 2016).

Recent identification of genes associated with susceptibility to Alzheimer’s disease provided basis for establishing the first non-descriptive link between inflammatory processes and development of AD pathology (Heppner, Ransohoff, Becher, 2015). Mutations in genes coding for triggering receptor expressed on myeloid cells 2 (TREM2) and myeloid cell surface antigen CD33 lead to a significantly increased risk of AD through impaired induction of inflammatory processes (Bradshaw et al., 2013; Jonsson et al. 2013)

Furthermore, studies on transgenic mice demonstrated that experimental induction of neuroinflammation initiated by administration of lipopolysaccharide (LPS) leads to an increase in amyloid beta deposition (Sheng et al., 2003; Lee et al., 2008).

It has been demonstrated that TNF- can potentiate the astroglial response, driving the neuroinflammatory process (Hensley, 2010).TNF-along with interleukin-1 and interferon-can induce the cleavage of the amyloid precursor protein (APP) by gamma-secretase via activation of the mitogen activated protein kinases (MAPK) pathway (Liao et al. 2004). TNF-is also capable of stimulating the NF- signalling that results in an increase in the production of amyloid beta (A (Chen et al. 2012).

Thus, an increasing amount of evidence suggests that modulation of inflammation through targeting TNF- may be a potential therapeutic strategy for AD.

**TNF-** α**I**

TNF-alpha is a powerful cytokine involved in the chronic inflammatory response (Akiyama, et al., 2000). Tarkowski et al. (2003) revealed a 25-fold difference in the levels of TNF-alpha in patients with AD compared to controls. Increasing evidence for the role of TNF-I in alleviating AD-related pathology prompted the first administration of Etanercept for primary progressive aphasia (Tobinick, 2008). Significant cognitive benefits were observed following the first dose of treatment. The results of this study suggested that TNF-alpha may play a pivotal role in the pathology of AD and exemplified its potential as a new therapeutic target.

**Aims and objectives of the current review**

Previous non-systematic reviews have reported on the mechanism of action of TNF- and the possible benefits of TNF-alpha downregulation in AD (Cheng et al., 2014; McCaulley and Grush, 2015). The previous reviews explored the effects of Etanercept, Infliximab, Pentoxifylline and Thalidomide on AD pathology, with little critical appraisal. To the authors' knowledge, no systematic review of studies investigating the role of TNF-alpha in the pathogenesis of AD has been published. Thus, the objective of the current review was to conduct a systematic and critical analysis of the available evidence from both animal and human studies to establish whether targeting TNF-alpha is a feasible strategy for the treatment of AD and whether this class of drugs has a potential to be tested in a large-scale human trial. Four main categories of outcomes were focused on: cognition and behaviour, reduction in brain tissue mass, presence of plaques and tangles, and synaptic function. Neuropathological features were the main focus of treatment as they are the main trigger of the chronic inflammatory response seen in these individuals (Zotova, Nicoll, Kalaria, Holmes, & Boche, 2010). It was beyond the scope of this review to investigate the effect of TNF-I on inflammation markers.

METHODS

**Literature search**

Six databases (PubMed, Embase, PsychINFO, Web of Science, Scopus and the Cochrane Library) were searched on 26th of October 2016 using the following search terms: (etanercept OR infliximab OR adalimumab OR certolizumab OR golimumab OR pentoxiflylline OR “tumor necrosis factor inhibitor” OR “TNF inhibitor” OR “tumour necrosis factor inhibitor” OR “tumour necrosis factor-alpha inhibitor” OR “TNF-alpha inhibitor”) AND (dement\* OR alzheim\* OR “cognitive decline” OR “cognitive dysfunction” OR “cognitive impairment” OR “cognitive deficit” OR “memory decline” OR “memory dysfunction” OR “memory impairment” OR “memory deficit” OR “neuropsychological test”). Etanercept, infliximab, adalimumab, certolizumab, golimumab, pentoxiflylline are TNF-I currently used for the treatment of rheumatoid arthritis (RA).

**Inclusion/exclusion criteria**

Studies were included if they met the following criteria: (1) published in a peer-reviewed journal without any language restrictions; (2) report original work; (3) conducted on animal subjects or human participants; (4) the intervention had to include an administration of a TNF-I or a genetic intervention leading to ablation of the TNF receptor (TNFR); (5) animal studies had to include transgenic or non-transgenic models of AD; and (6) human participants had to be diagnosed with AD. Conference proceedings, case studies, research protocols and unpublished dissertations or theses were excluded. In addition, studies on cell cultures were excluded.

**Screening and data extraction**

Studies were blindly and independently screened by two raters (JE and GR). Initially, titles and abstracts were screened and then full-text articles were retrieved for all potentially relevant studies. Discrepancies were resolved through discussion with an independent reviewer (RG). Two raters (JE and GR) blindly and independently extracted data on study characteristics, methodology of the study and outcomes with respect to neuropsychiatric and neurohistopathological findings (as outlined in the Introduction). Again, any discrepancies were resolved through discussion with an independent reviewer (RG).

**Quality assessment of methodology**

The methodological quality of studies was assessed to identify potential biases, confounding factors and any errors that could affect the interpretation of the results. There is no agreed instrument for assessing methodology and risk of bias in animal studies (Krauth, Woodruff, & Bero, 2013). Consequently, a quality assessment tool was developed for the purposes of this review based on criteria proposed by Krauth, Woodruff & Bero (2013). Some of the criteria were unique to animal studies and allowed for the measurement of bias, reporting and methodological issues. The EPHPP Quality Assessment Tool (Effective Public Health Practice Project, 2009) was used for human studies as it can be applied to all study designs. The quality of studies was evaluated in the following categories: selection bias, study design, confounder, blinding, data collection methods, withdrawals and drop-outs, intervention integrity and statistical analysis (see Appendix E). The methodological quality of included studies was assessed by two blind, independent raters (JE and GR), with any discrepancies in ratings being resolved through discussion with an independent reviewer (RG).

RESULTS

**Identification and Characteristics of Included Studies**

As shown in Figure 1, 1038 potentially relevant studies were initially identified, from which 477 duplicates were removed, yielding a total of 561 potentially relevant studies. After initial screening of titles and abstracts, 526 studies were excluded. This resulted in the extraction of 35 full-text articles, 16 of which met the inclusion criteria.

**Study characteristics**

**Animal studies**

Thirteen animal studies assessing the potential use of TNF-I in the treatment of AD were identified (see Appendix A for detailed characteristics) (Cavanagh, et al., 2016) (Detrait, Danis, Lamberty, & Foerch, 2014) (Gabbita, et al., 2012) (He, Cheng, Staufenbiel, Li, & Shen, 2012) (Kim, et al., 2016) (McAlpine, et al., 2009) (Medeiros, et al., 2007) (Medeiros, et al., 2010) (Montgomery, et al., 2011) (Roerink, et al., 2015) (Russo, et al., 2012) (Shi, et al., 2011) (Tweedie, et al., 2012). The studies were very heterogenous. Transgenic mice were subjects in 9 out of 13 studies (Cavanagh, et al., 2016; Gabbita, et al., 2012; He, Cheng, Staufenbiel, Li, & Shen, 2012; McAlpine, et al., 2009; Medeiros, et al., 2007; Medeiros, et al., 2010; Montgomery, et al., 2011; Shi, et al., 2011; Tweedie, et al., 2012).Three studies used non-transgenic mice (Detrait et al., 2014; Kim, et al., 2016; Russo, et al., 2012) and one was conducted on rats as well as transgenic mice (Tweedie, et al., 2012). The most common transgenic model of AD was 3xTg-AD type and was used in four studies (Gabbita, et al., 2012; McAlpine, et al., 2009; Montgomery, et al., 2011; Tweedie, et al., 2012). Aβ injections were used in five studies to induce similar changes to those seen in AD (Detrait et al., 2014) (Kim, et al., 2016; Medeiros, et al., 2007; Medeiros, et al., 2010; Russo, et al., 2012). The number of animals was unreported in the majority of studies. Only three of them stated this number, which ranged from nine to twenty-two (Roerink, et al., 2015; Shi, et al., 2011; Tweedie, et al., 2012). Consequently, it was not possible to calculate effect sizes. The most frequently used type of TNF-I was 3,6’-dithiothalidomide, administered in three studies (Gabbita, et al., 2012; Russo, et al., 2012; Tweedie, et al., 2012). The methods of drug delivery included intraperitoneal, intracerebroventricular, subcutaneous injections and stereotactic infusion. Peripheral administration via an intraperitoneal injection was the most common intervention, used in seven studies (Gabbita, et al., 2012; He et al., 2012; McAlpine, et al., 2009; Medeiros, et al., 2010; Russo, et al., 2012; Shi, et al., 2011; Tweedie, et al., 2012). The length of treatment ranged from one to 90 days. One paper did not report the duration of intervention (Montgomery, et al., 2011).

**Human studies**

Three studies on humans were identified (see Appendix B for detailed characteristics and Appendix C for inclusion/exclusion criteria), which were heterogeneous in a number of areas. The types of study design included a randomised double-blind controlled trial (Butchart, et al., 2015), nested case-control study (Chou, Kane, Ghimire, Gautam, & Gui, 2016) and a prospective, single centre, open-label pilot study (Tobinick et al., 2006). The number of participants ranged from 15 to 325. With respect to diagnosis, standard clinical criteria were used to diagnose AD in two studies (Butchart, et al., 2015; Tobinick et al., 2006) and both RA and AD in one study (Chou et al., 2016). Where reported, the age of participants ranged from 18 to 94 years, with the mean age ranging from 72.4 to 76.7 years (Butchart, et al., 2015; Tobinick et al., 2006). The mean Mini–Mental State Examination (MMSE) score in two out of three interventional studies that provided these data was similar: 18.2 and 20.3 (Butchart, et al., 2015; Tobinick et al., 2006). All studies recruited participants of both sexes: the mean percentage of female participants was 60%.

Administration of etanercept was the primary intervention in two out of three studies (Tobinick et al., 2006; Butchart, et al., 2015). Chou et al. (2016) carried out an observational study that aimed to determine the relative risk of AD in a cohort of patients receiving TNF-I for RA in comparison with RA individuals without AD. In the study by Tobinick et al. (2006), etanercept was administered perispinally, in contrast to the study by Butchart et al. (2015) which involved a subcutaneous injection. Butchart et al. (2005) failed to report the details of the process of participant recruitment. The study carried out by Tobinick et al. (2006) recruited individuals from the community. Chou et al. (2016) performed a search in the Verisk Health claims database to obtain a cohort of participants with a diagnosis of AD and RA and RA only as a control. Patients received treatment for 6 months in the studies carried out by Tobinick et al. (2006) and Butchart et al. (2005). The length of treatment could not be determined in the study by Chou et al. (2016) due to its retrospective study design.

**Quality Assessment**

**Animal Studies**

Ratings of the methodological quality of included animal studies are provided in Appendix D. Only two studies reported that treatment was allocated randomly (Shi, et al., 2011; Detrait et al., 2014). These studies also explicitly stated that the investigator involved in the experiment was blinded to the intervention (Shi, et al., 2011) (Detrait et al., 2014). Blinding was only partially described in three studies (He et al., 2012) (Kim, et al., 2016) (Russo, et al., 2012). None of the studies provided information on how the number of study animals was calculated. The requirement for compliance with the Animal Welfare Act was met by all studies. Four studies declared no financial conflict of interest (Cavanagh, et al., 2016) (Detrait et al., 2014) (Roerink, et al., 2015) (Shi, et al., 2011). The statistical methods used to analyse the results obtained were partially adequate (Cavanagh, et al., 2016) (Kim, et al., 2016) (Medeiros, et al., 2007) (Montgomery, et al., 2011) (Shi, et al., 2011) (Russo, et al., 2012) or fully explained (Detrait et al., 2014) (Gabbita, et al., 2012) (He et al., 2012) (McAlpine, et al., 2009) (Tweedie, et al., 2012) (Medeiros, et al., 2010) in all studies, except one (Roerink, et al., 2015). The presence of any comorbidities in test animals was not reported in any of the studies. All of the studies provided partial information on the characteristics of the animal used, such as species, strain, genetic background, supplier, sex and weight. None of the studies, however, reported enough detail to fully meet this criterion. No mention was made in any of the studies as to whether the dose-response pattern was suitable to address the hypothesis. All of the included studies failed to report if any animals had been withdrawn from the experiment before its completion. The time window for assessing the outcome of the experiments was rated as adequate in twelve out of thirteen studies (Cavanagh, et al., 2016) (Detrait et al., 2014) (Gabbita, et al., 2012) (He et al., 2012) (Kim, et al., 2016) (McAlpine, et al., 2009) (Medeiros, et al., 2007) (Medeiros, et al., 2010) (Roerink, et al., 2015) (Russo, et al., 2012) (Tweedie, et al., 2012).

**Human Studies**

Ratings of the quality of human studies are listed in Appendix E. The participants in the study by Butchart et al. (2015) were likely to be representative of the target population. There was a partial risk of selection bias in the study by Chou et al. (2016) and Tobinick et al. (2006). Two out of three studies were randomized and the study design was rated as adequate (Butchart, et al., 2015) (Tobinick et al., 2006). The study by Chou et al. (2016) was a retrospective case control analysis (Chou et al., 2016). The confounding factors were well-controlled in one study (Butchart, et al., 2015). It is unclear whether participants of the two remaining studies were exposed to any factors that may have affected the results (Chou et al., 2016) (Tobinick et al., 2006). Blinding was adequate in only one study (Butchart, et al., 2015) and partially adequate in the two remaining ones (Chou et al., 2016) (Tobinick et al., 2006). The data collection methods were valid and reliable in all studies. Any withdrawals or drop-outs were appropriately reported in two studies (Butchart, et al., 2015) (Tobinick et al., 2006). The integrity of the intervention was adequate in the study by Chou et al. (2016) and partially adequate in Butchart et al. (2015) The study by Tobinick et al. (2006) was a pilot study hence the intervention integrity was rated as inadequate.

**Results of included studies**

The findings in each subcategory are discussed below (see Appendix F for a summary of the key outcomes).

**Cognition and behaviour**

In all studies that assessed changes in cognition and behaviour, the effect of TNF-I was beneficial. Cavanagh et al. (2016) showed that an increase in hippocampus-dependent synaptic function, an early pathological sign of AD, can be reversed by an administration of XPro1595.

Aβ-associated cognitive deficits in mice were also diminished by a subcutaneous injection of the TNF receptor 2 fused to a fragment crystallisable (Fc) domain used clinically for the treatment of RA (Detrait et al., 2014). The animals showed a dose-related response in alternation percentage in the Y-maze, with a complete reversal of cognitive deficits at 30mg/kg (Detrait et al., 2014).

Changes in exploration of the radial arm on administration of 3,6’-dithiothalidomide, but not thalidomide, in 3xTg mice were observed in one experiment (Gabbita, et al., 2012). Consistent with previous findings, 3,6’-dithiothalidomide was found to ameliorate the cognitive deficits induced by an injection of Aβ1-42.

Kim et al. (2016) injected mice with Aβ1-42 and performed a novel object recognition test after administration of Infliximab. Results showed that the drug counteracted the Aβ1-42 memory impairment (Kim, et al., 2016). Tweedie et al. (2012) provided further evidence for the beneficial effect of 3,6’-dithiothalidomide-treated on cognition and demonstrated that it is capable of decreasing levels of phosphorylated tau (Tweedie, et al., 2012).

Medeiros et al. (2007) investigated the effect of Aβ1-40 injection on TNFR1 knock-out and iNOS-knock out mice. It was found that genetic and pharmacological inhibition of these signaling pathways ameliorated learning and memory deficits in AD-mice models.

Another study revealed that treatment with a COX-2 inhibitor and AbTNF-alpha in 57BI/6 and TNFR1 knockout mice prevented cognitive decline and led to an improvement in spatial learning deficits (Medeiros, et al., 2010).

**Reduction in brain tissue mass**

None of the studies investigated the effect of TNF-I on brain tissue mass.

**Presence of plaques and tangles**

Although the majority of included animal studies reported a reduction in the quantity of neuropathological features, the results were not fully consistent. Gabbita et al. (2012) showed no differences in the number of 6E10 positively stained cells in the hippocampus on thalidomide and 3,6’-dithiothalidomide administration (Gabbita, et al., 2012). Contradicting results were obtained from a different study, which not only showed a decrease in the number of 6E10+ cells, but also in the total levels of Aβ (He et al., 2012). Western blotting performed on tissue samples from both thalidomide-treated and non-treated mice demonstrated a decrease in the activity of a β secretase, BACE1 (He et al., 2012) (O'Brien & Wong, 2011).

McAlpine et al. (2009) investigated the effect of short- and long-term inhibition of TNF-alpha signaling on the amyloid plaque burden in lipopolysaccharide (LPS-challenged mice. The first method involved inhibition of TNF signaling for a period of one month using XENP345, while the lentivirus-based approach blocked the pathway for a period of at least one year. A significant decrease in the number of 6E10-immunoreactive cells in the hippocampus of XENP345-treated and the lentivirus-infected mice was seen (McAlpine, et al., 2009).

A semi-quantitative analysis of brain samples from APP/PS1 mutants following an injection with Infliximab demonstrated a 40-60% decrease in Aβ deposits as well as a reduction in levels of hyperphosphorylated tau (Shi, et al., 2011).

**Synaptic function**

Despite increasing evidence for synaptic dysfunction in AD, only three out of thirteen studies investigated this process. Cavanagh et al. (2016) assessed the effect of XPro1595 on synaptic deficits in transgenic mice. An overall enhancement of synaptic function in pre-plaque animals was observed. A study on 3xTg-ADxTNG-RI/RII knock-out mice confirmed the findings that synaptic dysfunction appears before the onset of pathology in animal models of AD (Cavanagh et al. 2016). Electrophysiological properties of tissue samples from mice injected with Aβ demonstrated that Aβ1-42 hinders the process of long-term depression. This effect was reversed following the administration of Infliximab (Kim et al., 2016).

**Human Studies**

The included human studies investigating the link between TNF-I and the risk of AD only assessed changes in cognition and behaviour (see Appendix G for a summary of the key outcomes). Butchart et al. (2015) conducted a double-blind study with patients with mild to moderate AD to determine the tolerability and safety of etanercept. There were 20 participants in the etanercept group, and 21 in the placebo group. Adverse events were less common in the etanercept group (42 events) compared with the control group (55 events); however, this difference was not statistically significant. The nested case-control analysis performed by Chou et al. found a negative association between the use of etanercept and the risk of AD. Although this study did not examine the effect of TNF-I on any of this review’s main outcomes, it was included as it provides additional evidence for the use of TNF-I in AD. Tobinick et al. (2006) conducted a prospective, single-centre pilot study that recruited 15 patients within the residing community. The participants were administered a weekly dose of Etanercept for six months. The results of the study demonstrated a significant difference between the etanercept and placebo group in MMSE, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and Severe Impairment Battery (SIB) over six months (Tobinick et al., 2006).

DISCUSSION

The main findings of this systematic review will be summarized below and compared with the findings of previous reviews. The clinical and research implications and strengths and limitations of the current review will also be discussed.

**Previous findings**Evidence from animal studies presented in this review supports the mechanism underlying the use of TNF-I in ameliorating AD pathology, as described by Cheng, Shen, & Li, (2014). A wider range of TNF-I were explored in the current systematic review in comparison with the aforementioned narrative review (Cheng et al., 2014), and so the potential of this class of drugs might have been previously underestimated. Consistent with the findings of McCaulley and Grush (2015), TNF-I were found to have a beneficial effect in patients with AD in the current review. However, a more detailed analysis conducted in the current review compared to the previous narrative review (McCaulley & Grush, 2015) revealed many flaws in the quality and significance of existing data.

**Research implications**

The role of the TNF signaling pathway has been a subject of many other studies, some of which may have therapeutic implications for AD patients. The evidence provided by Medeiros et al. (2007) suggested that TNF-alpha might promote the expression of inducible nitric oxide synthase (iNOS) in the CNS, leading to a more rapid progression of the pathology. Hence, modulating the levels of TNF-alpha in parallel with iNOS could be a potential therapeutic strategy for AD (Medeiros et al., 2007).

The open-label pilot study conducted by Tobinick et al. (2006) included the administration of Etanercept, in addition to the standard medication recommended in the treatment of AD. For this reason, the contribution of these drugs to the improvement seen in the participants of this study cannot be determined. Future studies should focus on separating the effect of TNF-I from the already established treatment to determine their true effectiveness. The analysis of the methodological quality of the study revealed a possible conflict of financial interest (Tobinick et al., 2006). Thus, the conclusions from this study may be subject to bias and so the study should be replicated.

The results obtained from Roerink et al. (2015) contradicted the study by Tobinick et al. (2006). The perispinal injection of radiolabeled cetuximab, entanercept and anakinra showed that in eight out of nine rats the compounds were not able to cross the brain-blood barrier (BBB) (Roerink, et al., 2015). This finding suggests that high-molecular weight compounds may not be effective in the treatment of AD due to their low penetrability. The importance of molecular weight on the observable therapeutic effects has also been discussed by McCaulley and Grush (2015). Small molecular TNF-alpha modulators such as thalidomide and 3,6’-dithiothalidomide should be tested.

In the study conducted by Chou et al. (2016) the analysis period ranged from 2000-2007, with the minimum age of participants being 18 years. Hence, the drug regime might have changed substantially over this period. A case-control analysis, including more recent data should be conducted.

The route of drug administration may also play an important role in achieving the most beneficial outcome. While Butchart el al (2015) chose to administer etanercept subcutaneously, Tobinick et al. (2005) injected the drug perispinally. Future research should focus on comparing the two methods.

The effectiveness of pentoxifylline on slowing down the progress of mental deterioration in patients with a diagnosis of multi-infarct dementia has also been investigated (European Pentoxifylline Multi-Infarct Dementia [EPMID] Study Group, 1996). A significant improvement on the Gottfries-Bråne-Steen (GBS) scale was seen. However, the study reported no decline in MMSE score over a 9-month period, which might imply that patients diagnosed with AD did not participate in the trial or that the treatment period was too short. Investigating the effect of Pentoxifylline on patients with a diagnosis of AD would be desirable.

Butchart et al. (2015) used six neuropsychometric tests to assess the effect of subcutaneous Etanercept on secondary clinical outcomes. After correcting for multiple comparisons, no statistically significant differences in scores on the neuropsychometric tests were found (Butchart, et al., 2015). Based on these results, it may be suggested that a TNF-I with different pharmacokinetic properties should be tested in a clinical trial. Evidence from a study of the effect of thalidomide, etanercept and infliximab on rat models of dementia showed that the thalidomide-treated group performed best in the Morris water maze test (Elcioglu, et al., 2015). This finding suggests that future research should investigate the effect of thalidomide on AD pathology.  
  
Currently, only limited evidence of the effect of TNF-I on synaptic function is available and more research in this area is required. None of the studies measured reduction in brain tissue mass. Given that this is a good indication of disease severity, future research should take this into consideration.

**Clinical implications**

It has been shown that an increase in synaptic function of glutamatergic neurons occurs before the development of AD pathology, subsequently leading to deleterious effects on cognition (Dickerson, et al., 2005). The administration of an TNF-I in the study by Cavanagh et al. (2016) diminished the observed abnormalities. For this reason, treatment with TNF-I could prove beneficial for patients in the initial stages of the disease.

**Strengths and limitations**The main strengths of the review was that a broad range of studies were searched across six databases. Furthermore, extracting the information on research design and analytical methods enabled classification of the quality and impact of studies. The main limitations of the review were that it was not possible to statistically synthesize the results of the included studies as the sample size was not stated in the vast majority of them. The conclusions are therefore only descriptive and lack quantitative synthesis. Non-peer reviewed studies including posters and dissertations were also excluded. Furthermore, grey literature sources were not included in the initial screening, which may have resulted in publication bias.

**Conclusion**

Despite high heterogeneity in interventions assessed and outcomes measured, it can be concluded that TNF-I have a beneficial effect on cognition and behaviour based on evidence from animal studies of AD models. All studies, except one, showed that the administration of TNF-I ameliorates AD-related pathology. Results from an observational study and a pilot study suggested that treatment with TNF-I may be beneficial for patients with AD. However, due to the conflict of interest in one of the studies and small sample size, caution should be expressed when interpreting the results. Chou et al. (2016) showed that out of all therapeutic drugs for RA, only treatment with TNF-I correlated with a decreased risk of AD. Taken together, there is sufficient data to suggest that a large scale randomized controlled trial assessing the effectiveness of TNF-I should be conducted on humans.

# References

Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Wyss–Coray, T. Neuroinflammation Working Group (2000). Inflammation and Alzheimer’s disease. Neurobiology of Aging, 21(3), 383–421.

Alvarez, A., Cacabelos, R., Sanpedro, C., Garcia-Fantini, M., & Aleixandre, M. (2007). Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiology of Aging, 533-536.

Alzheimer’s Association. (2016). Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia.

Bäckman, L., Jones, S., Berger, A.-K., Laukka, E. J. and Small, B. J. (2004), Multiple cognitive deficits during the transition to Alzheimer's disease. Journal of Internal Medicine, 256: 195–204. doi:10.1111/j.1365-2796.2004.01386.x

Bassiony, M., Steinberg, M., Warren, A., Rosenblatt, A., Baker, A., & Lyketsos, C. (2000). Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates. International journal of geriatric psychiatry, 15(2), 99-107.

Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010). Genetics of Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 23(4), 213–227. <http://doi.org/10.1177/0891988710383571>

Bronzuoli, M. R., Iacomino, A., Steardo, L., & Scuderi, C. (2016). Targeting neuroinflammation in Alzheimer’s disease. Journal of Inflammation Research, 9, 199–208. <http://doi.org/10.2147/JIR.S86958>

Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., … De Jager, P. L. (2013). CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology. Nature Neuroscience, 16(7), 848–850. http://doi.org/10.1038/nn.3435

Brookmeyer, R., Corrada, M., Curriero, F., & Kawas, C. (2002). Survival following a diagnosis of Alzheimer disease. Archives of Neurology,59 (11), 1764-1767.

Brunnström, H. R., & Englund, E. M. (2009). Cause of death in patients with dementia disorders. European Journal of Neurology,16(4), 488-492.doi: 10.1111/j.1468-1331.2008.02503.x.

Butchart, J., Brook, L., Hopkins, V., Teeling, J., Püntener, U., Culliford, D., … Holmes, C. (2015). Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology, 84(21), 2161–2168. <http://doi.org/10.1212/WNL.0000000000001617>

Casley, C. S., Land, J. M., Sharpe, M. A., Clark, J. B., Duchen, M. R., & Canevan, L. (2002). β-Amyloid Fragment 25–35 Causes Mitochondrial Dysfunction in Primary Cortical Neurons. Neurobiology of Disease, 258-267.

Cavanagh, C., Tse, Y. C., Nguyen, H.-B., Krantic, S., Breitner, J. C., Quirion, R., & Wong, T. P. (2016). Inhibiting tumor necrosis factor-a before amyloidosis prevents synaptic deficits in an Alzheimer’s disease model. Neurobiology of Aging,4, 41-49. <https://doi.org/10.1016/j.neurobiolaging.2016.07.009>

Chavant, F., Deguil, J., Pain, S., Ingrand, I., Milin, S., Fauconneau, B., Lafay-Chebassier, C. (2010). Imipramine, in Part through Tumor Necrosis Factor alpha Inhibition Prevents Cognitive Decline and beta-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease. The Journal of Pharmacology and Experimental Therapeutics, 332 (2) 505-514; DOI: <https://doi.org/10.1124/jpet.109.162164>

Chia-Hsiung Chen, Weihui Zhou, Shengchun Liu, Yu Deng, Fang Cai, Masahide Tone, Yukiko Tone, Yigang Tong, Weihong Song. (2012) Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease, International Journal of Neuropsychopharmacology, 15 (1), 77- 90, <https://doi.org/10.1017/S1461145711000149>

Cheng, X., Shen, Y., & Li, R. (2014). Targeting TNF: a therapeutic strategy for Alzheimer's disease. Drug Discovery Today, 19(11), 1822-7. doi: 10.1016/j.drudis.2014.06.029.

Chou, R. C., Kane, M., Ghimire, S., Gautam, S., & Gui, J. (2016). Treatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis. CNS Drugs, 30(11):1111-1120.

Detrait, E. R., Danis, B., Lamberty, Y., & Foerch, P. (2014). Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice. Neurochemistry International,72, 10-13. <https://doi.org/10.1016/j.neuint.2014.04.001>

Dickerson, B. C., Salat, D. H., Greve, D. N., Chua, E. F., Rand-Giovannetti, E., Rentz, D. M., … Sperling, R. A. (2005). Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology, 65(3), 404–411. http://doi.org/10.1212/01.wnl.0000171450.97464.49

Effective Public Health Practice Project. (2009). Quality Assessment Tool for Quantitative Studies. Retrieved February 01, 2017, from <http://www.ephpp.ca/PDF/Quality%20Assessment%20Tool_2010_2.pdf>

Elcioglu, K. H., Kabasakal, L., Tufan, F., Elcioglu, Ö. H., Solakoglu, S., Kotil , T., & Karan, M. A. (2015). Effects of systemic Thalidomide and intracerebroventricular Etanercept and Infliximab administration in a Streptozotocin induced dementia model in rats. Acta Histochemica, 117(2), 176-181. <https://doi.org/10.1016/j.acthis.2014.12.002>

Linda J. Van Eldik, Maria C. Carrillo, Patricia E. Cole, Dominik Feuerbach, Barry D. Greenberg, James A. Hendrix, Matthew Kennedy, Nick Kozauer, Richard A. Margolin, José L. Molinuevo, Reinhold Mueller, Richard M. Ransohoff, Donna M. Wilcock, Lisa Bain, Kelly Bales. (2016) The roles of inflammation and immune mechanisms in Alzheimer's disease, In Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2 (2), 99-109, https://doi.org/10.1016/j.trci.2016.05.001.

European Pentoxifylline Multi-Infarct Dementia (EPMID) Study Group . (1996). European Pentoxifylline Multi-Infarct Dementia Study. European Neurology 36(5), 315-321.

Francis, P., Palmer, A., Snape, M., & Wilcock, G. (1999). The cholinergic hypothesis of Alzheimer’s disease: a review of progress. Journal of Neurology, Neurosurgery, and Psychiatry, 66(2), 137–147.

Gabbita, S. P., Srivastava, M. K., Eslami, P., Johnson, M. F., Kobritz, N. K., Tweedie, D., … Harris-White, M. E. (2012). Early intervention with a small molecule inhibitor for tumor nefosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. Journal of Neuroinflammation, 9, 99. http://doi.org/10.1186/1742-2094-9-99 Gordon, J., Amini, S., & White, M. K. (2011). General overview of neuronal cell culture. Methods in molecular biology, 1-8.

Gorelick, P. (2010). Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences,1207, 155-162. doi: 10.1111/j.1749-6632.2010.05726.x.

Grossman, M. (2010). Primary progressive aphasia: clinicopathological correlations. Nature Reviews. Neurology, 6(2), 88–97. http://doi.org/10.1038/nrneurol.2009.216

Gylys, K. H., Fein, J. A., Yang, F., Wiley, D. J., Miller, C. A., & Cole, G. M. (2004). Synaptic Changes in Alzheimer’s Disease : Increased Amyloid-β and Gliosis in Surviving Terminals Is Accompanied by Decreased PSD-95 Fluorescence. The American Journal of Pathology, 165(5), 1809–1817.

He, P., Cheng, X., Staufenbiel, M., Li, R., & Shen, Y. (2013). Long-Term Treatment of Thalidomide Ameliorates Amyloid-Like Pathology through Inhibition of β-Secretase in a Mouse Model of Alzheimer’s Disease. PLoS ONE, 8(2), e55091. <http://doi.org/10.1371/journal.pone.0055091>

**Heppner F.L., Ransohoff R.M., Becher B.; (2015)** Immune attack: the role of inflammation in Alzheimer disease**.** Nature Reviews Neuroscience, 16(6), p.358. doi:10.1038/nrn3880

Hensley, K. (2010). Neuroinflammation in Alzheimer’s Disease: Mechanisms, Pathologic Consequences, and Potential for Therapeutic Manipulation. Journal of Alzheimer’s Disease : JAD, 21(1), 1–14. http://doi.org/10.3233/JAD-2010-1414

Hwang, T., Masterman, D., Ortiz, F., Fairbanks, L., & Cummings, J. (2004). Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Disease and Associated Disorders,18(1), 17-21.

Hynd, M., Scott, H., & Dodd, P. (2004). Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochemistry International,45(5), 583-595. <https://doi.org/10.1016/j.neuint.2004.03.007>

Iqbal, K., Flory, M., & Soininen, H. (2013). Clinical symptoms and symptom signatures of Alzheimer's disease subgroups. Journal of Alzheimer's Disease, 37(3), 475-81. doi: 10.3233/JAD-130899.

Kaur, G., & Dufour, J. M. (2012). Cell lines: Valuable tools or useless artifacts. Spermatogenesis, 2(1), 1–5. http://doi.org/10.4161/spmg.19885

Kim, H. D., Choi, S.-M., Jho , J., Park, M.-S., Kang, J., Park, S. J.,Kim, B. C. (2016). Infliximab ameliorates AD-associated object recognition memory impairment. Behavioural Brain Research,311, 384-391. <https://doi.org/10.1016/j.bbr.2016.06.001>

Krauth, D., Woodruff, T. J., & Bero, L. (2013). Instruments for Assessing Risk of Bias and Other Methodological Criteria of Published Animal Studies: A Systematic Review. Environmental Health Perspectives, 121(9), 985–992. http://doi.org/10.1289/ehp.1206389

Kurz, A., & Förstl, H. (1999). Clinical features of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci, 249(6), 288-290. <https://doi.org/10.1007/s004060050101>

Lee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W., & Hong, J. T. (2008). Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. Journal of Neuroinflammation, 5, 37. http://doi.org/10.1186/1742-2094-5-37

Li, S., Jin, M., Koeglsperger, T., Shepardson, N., Shankar, G., & Selkoe, D. (2011). Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 31(18), 6627–6638. <http://doi.org/10.1523/JNEUROSCI.0203-11.2011>

Liao Y.F., Wang B.J., Cheng H.T., Kuo L.H., Wolfe M.S. (2004). Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem. ;279(47):49523–4932

Lyketsos, C., Rosenblatt, A., & Rabins, P. (2004). Forgotten frontal lobe syndrome or "Executive Dysfunction Syndrome". Psychosomatics,45(3), 247-255. <https://doi.org/10.1176/appi.psy.45.3.247>

McAlpine, F. E., Lee, J.-K., Harms, A. S., Ruhn, K. A., Blurton-Jones, M., Hong, J., Tansey, M. G. (2009). Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiology of Disease, 34(1), 163–177.

McGeer PL, Rogers J, McGeer EG, Sibley J. Anti-inflammatory drugs and Alzheimer’s disease? Lancet. 1990;335:1037

Mark E. McCaulley and Kira A. Grush, “Alzheimer’s Disease: Exploring the Role of Inflammation and Implications for Treatment,” International Journal of Alzheimer’s Disease, vol. 2015, Article ID 515248, 10 pages, 2015. doi:10.1155/2015/515248

Medeiros, R., Figueiredo, C. P., Pandolfo, P., Duarte, F. S., Prediger, R. D., Passos, G. F., & Calixto, J. B. (2010). The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behavioural Brain Research, 209(1), 165-173. <https://doi.org/10.1016/j.bbr.2010.01.040>

Medeiros, R., Prediger, R. D., Passos, G. F., Pandolfo, P., Duarte, F. S., Franco, J. L., Calixto, J. B. (2007). Connecting TNF-alpha Signaling Pathways to iNOS Expression in a Mouse Model of Alzheimer’s Disease: Relevance for the Behavioral and Synaptic Deficits Induced by Amyloid beta Protein. Neurobiology of Disease,27(20), 53894-5404. https://doi.org/10.1523/JNEUROSCI.5047-06.2007

Montgomery, S. L., Mastrangelo, M. A., Habib, D., Narrow, W. C., Knowlden, S. A., Wright, T. W., & Bowers, W. J. (2011). Ablation of TNF-RI/RII Expression in Alzheimer’s Disease Mice Leads to an Unexpected Enhancement of Pathology: Implications for Chronic Pan-TNF-α Suppressive Therapeutic Strategies in the Brain. The American Journal of Pathology, 179(4), 2053–2070. http://doi.org/10.1016/j.ajpath.2011.07.001

Mudher, A., & Lovestone, S. (2002). Alzheimer's disease – do tauists and baptists finally shake hands? Trends in Neurosciences, 25 (1), 22-26.  <http://dx.doi.org/10.1016/S0166-2236(00)02031-2>

National Institute for Health and Clinical Excellence. (2006, May). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. Retrieved 03 20, 2017, from <https://www.nice.org.uk/guidance/ta111/documents/alzheimers-disease-donepezil-rivastigmine-galantamine-and-memantine-review-final-appraisal-document2>

O’Brien, R. J., & Wong, P. C. (2011). Amyloid Precursor Protein Processing and Alzheimer’s Disease. Annual Review of Neuroscience, 34, 185–204. <http://doi.org/10.1146/annurev-neuro-061010-113613>

Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia. 2010;58(7):831–838.

Ossowska, K. (1993). Disturbances in neurotransmission processes in aging and age-related diseases. Polish Journal of Pharmacology,45(2), 109-131.

Peila, R., & Launer, L. (2006). Inflammation and dementia: epidemiologic evidence. Acta neurologica Scandinavica. Supplementum,114, 102-106. doi:10.1111/j.1600-0404.2006.00693.x

Pharmaceutical Research and Manufacturers of America. (2015). Pharmaceutical Research and Manufacturers of America. Researching Alzheimer’s Medicines: Setbacks and Stepping Stones. Washington: PhRMA.

Roerink, M. E., Groen, R. J., Franssen, G., Lemmers-van de Weem, B., Boerman, O. C., & van der Meer, J. W. (2015). Central delivery of iodine-125–labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer’s disease. Alzheimer’s Research & Therapy, 7, 70. <http://doi.org/10.1186/s13195-015-0149-7>

Russo, I., Caracciolo, L., Tweedie, D., Choi, S.-H., Greig, N. H., Barlati, S., & Bosetti, F. (2012). 3,6′-Dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. Journal of Neurochemistry, 122(6), 1181–1192. http://doi.org/10.1111/j.1471-4159.2012.07846.x.

Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012, March). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews,11(3), 191-200. doi:10.1038/nrd3681

Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine:, 1(1), a006189. <http://doi.org/10.1101/cshperspect.a006189>

Shankar, G. M., & Walsh, D. M. (2009). Alzheimer’s disease: synaptic dysfunction and Aβ. Molecular Neurodegeneration, 4, 48. http://doi.org/10.1186/1750-1326-4-48

Sheng, J. G., Bora S. H., Xu, G., Borchelt, D. R., Price D. L., Koliatsos, V. E. (2003), Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice, Neurobiology of Disease, 14 (1), 133-145, https://doi.org/10.1016/S0969-9961(03)00069-X.

Shi, J.-Q., Shen, W., Chen, J., Wang, B.-R., Zhong, L.-L., Zhu, Y.-W., Xu, J. (2011). Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Research,1368, 239-247.https://doi.org/10.1016/j.brainres.2010.10.053

Tarkowski, E., Liljeroth, A.-M., Minthon, L., Tarkowski, A., Wallin, A., & Blennow, K. (2003). Cerebral pattern of pro- and anti-inflammatory cytokines in dementias.61 (3), 255-260. https://doi.org/10.1016/S0361-9230(03)00088-1

Tobinick, E. (2008). Perispinal Etanercept Produces Rapid Improvement in Primary Progressive Aphasia: Identification of a Novel, Rapidly Reversible TNF-Mediated Pathophysiologic Mechanism. The Medscape Journal of Medicine, 10(6), 135.

Tobinick, E. (2011). Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease. Current Alzheimer research,9 (1), 99-109.

Tobinick, E., Gross, H., Weinberger, A., & Cohen, H. (2006). TNF-alpha Modulation for Treatment of Alzheimer’s Disease: A 6-Month Pilot Study. Medscape General Medicine, 8(2), 25.

Trivedi, S. C., Subramanyam, A. A., Pinto, C., & Gambhire, D. D. (2013). Neuropsychiatric symptoms in mild cognitive impairment: An analysis and its impact on caregiving. Indian Journal of Psychiatry, 55(2), 154–160. http://doi.org/10.4103/0019-5545.111454.

Tweedie, D., Ferguson, R. A., Fishman, K., Frankola, K. A., Van Praag, H., Holloway, H. W., Rosi, S. (2012). Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. Journal of Neuroinflammation, 9, 106. <http://doi.org/10.1186/1742-2094-9-106>

Yan, S. D., Roher, A., Schmidt, A. M., & Stern, D. M. (1999). Cellular Cofactors for Amyloid β-Peptide-Induced Cell Stress: Moving from Cell Culture to in Vivo. The American Journal of Pathology, 155(5), 1403–1411. Zanetti, O., Solerte, S. B., & Cantoni, F. (2009). Life expectancy in Alzheimer's disease (AD). Archives of gerontology and geriatrics,49 Supplement 1, 237-243, https://doi.org/10.1016/j.archger.2009.09.035

Zotova, E., Nicoll, J. A., Kalaria, R., Holmes, C., & Boche, D. (2010). Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimer’s Research & Therapy, 2(1), 1. http://doi.org/10.1186/alzrt24

Figure 1. PRISMA flow chart

Appendix A: Key characteristics of animal studies.

Appendix B: Key characteristics of human studies.

Appendix C: Inclusion and exclusion criteria for human studies.

Appendix D: Methodological quality of animal studies.

Appendix E: Methodological quality of human studies.

Appendix F: Outcomes of animal studies.

Appendix G: Outcomes of human studies.

**Appendix A:** Key characteristics of animal studies.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Authors** | Population | Model | Number of subject animals | Drug | Dose | Method of drug delivery | Length of treatment |
| **Cavanagh et al. (2016)** | Transgenic mice | TgCRND8 | unreported | XPro1595 | 10mg/kg | subcutaneous | 28 days |
| **Detrait et al. (2014)** | NTG | injected with Aβ25-35 or scAβ25-35 | unreported | Etanercept | 30mg/kg | subcutaneous | once a day on days 2, 4 and 6 |
| **Gabbita et al. (2012)** | Transgenic mice | 3xTgAD | unreported | 3,6-dithiothalidomide and thalidomide | 50mg/kg | intraperitoneal | daily for 70 days |
| **He et al. (2013)** | Transgenic mice | APP23 | Insufficient detail | Thalidomide | 100mg/kg | intraperitoneal | daily for 90 days or 3 days |
| **Kim et al. (2016)** | NTG | injected with Aβ1-42 | unreported | Infliximab | 2μg/3μl | intracerebroventricular | once in 24 hours |
| **McAlpine et al. (2009)** | Transgenic mice | 3xTgAD | unreported | DN-TNF XENP345 or DN-TNF | 0.1mg/kg/day | intraperitoneal | twice weekly for 28 days |
| **Medeiros et al. (2007)** | Transgenic mice | TNFR1-KO and injected with Aβ1-40 | unreported | AbTNF-α, aminoguanidine, JNK or pyrrolidine dithiocarbonate | AbTNF-α - 10ηg, aminoguanidine - 100mg/kg, JNK - 50mg/kg, or pyrrolidine dithiocarbonate - 100mg/kg | intracerebroventricular | 8 days |
| **Medeiros et al. (2010)** | Transgenic mice | Injected with Aβ1-40 | unreported | AbTNFα and COX-2 inhibitor NS398 | 1 mg/kg of NS398 and 10ng/mice of AbTNF-alpha | intraperitoneal | twice a day for 7 days |
| **Montgomery et al. (2011)** | Transgenic mice | 3xTg-ADxTNF-RI/RII KO | unreported | rAAV2 | 2μl | stereotactic infusion | unknown |
| **Roerink et al. (2015)** | NTG | Rats | 9 | cetuximab, etanercept anakinra | cetuximab - 146 kDetanercept - 51 kDa, anakinra - 17 kDa | perispinal injection | one injection |
| **Russo et al. (2012)** | NTG | injected with Aβ1-42 | unreported | 3,6-dithiothalidomide | 56mg/kg | intraperitoneal | daily for 14 days to explore hippocampal progenitor cell proliferation and daily for 5 weeks to look at progenitor cell survival and generation of newly derived neurons |
| **Shi et al. (2011)** | Transgenic mice | APP/PS1 | 20 | Infliximab | 150μl | intraperitoneal | daily for three days |
| **Tweedie et al. (2012)** | Transgenic mice and Rats | 3xTg-AD and LPS challenged rats | 22 | 3,6-dithiothalidomide | LPS: 56mg/kg 3xTg-AD: 42mg/kg | intraperitoneal | LPS: 14 days 3xTg-AD: daily for 42 days |

Note: Aβ = amyloid peptide; AbTNF-α= anti-TNF-α antibody; APP23=APPswedish mutation transgenic; COX-2= Cyclooxygenase 2; DN-TNF= dominant-negative tumor necrosis factor; JNK= c-Jun N-terminal kinase; kDa= kilodaltons; LPS=lipopolysaccharide; NTG= non-transgenic mice; rAAV2=recombinant adeno-associated virus serotype-2 (rAAV2); scAb = scrambled amyloid peptide; TNFR1-KO= TNF receptor 1-knockout; TNFR2:Fc= TNF receptor 2 fused to a Fc domain

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Study design | Number of participants | Diagnosis | Mean age [years], age range | Mean MMSE | Sex (% male) | Tx | Method of administration | Setting | Dose | Length of Tx [months] |
| **Butchart et al. (2015)** | double-blind RCT | 67 screened, 41 recruited and 33 completed (N=18 in etanercept group, N=15 in placebo) | Probable AD defined by the NINCDS criteria | 72.4, NK | 20.0 for Etanercept, 20.3 for placebo | 61 | Etanercept | subcutaneous | Single-centre | 50mg once weekly | 6 |
| **Chou et al. (2016)** | nested-case control | Identified=8,500,454  participants with RA=41,109  participants with AD=9253  total number with RA and AD=325 | ICD-9 for rheumatoid arthritis (RA) and a diagnosis of AD made at least 120 days before the diagnosis of RA | 76.5, ≥ 18 years | NK | 30 | methotrexate, prednisone, sulfasalazine, three anti-TNF agents (adalimumab, etanercept and infliximab) and an anti-CD20 agent (rituximab) | Etanercept- subcutaneous; other drugs-not stated | Commercially insured adults in the Verisk Health claims database | NK | NK |
| **Tobinick  et al. (2006)** | prospective, single-centre, open-label, pilot study | 15 | NINCDS-ADRDA Criteria for probable AD and DSM-IV criteria for AD | 76.7, 52-94 | 18.2 | 40 | Etanercept | perispinal | Community | 25-50mg once weekly | 6 |

**Appendix B:** Key characteristics of human studies.

Note: AD= Alzheimer’s disease; Anti-CD20= a new generation monoclonal antibody; DSM-IV= Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; ICD-9= International Statistical Classification of Diseases and Related Health Problems, Ninth Revision; MMSE= The Mini–Mental State Examination; NINCDS= National Institute of Neurological and Communicative Disorders and Stroke; NINCDS-ADRDA= National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; RA= rheumatoid arthritis; RCT= Randomised-controlled trial; Tx= treatment

**Appendix C:** Inclusion and exclusion criteria for human studies.

|  |  |  |
| --- | --- | --- |
|  | **Inclusion criteria** | **Exclusion criteria** |
| **Butchart et al. (2015)** | Modified Hachinski Ischemic Scale score <5 points, have a standardized MMSE\* score above 10 and below 27 points, have an informant spending at least 24 hours per week with the participant, and be capable of giving informed consent. Patients taking a cholinesterase inhibitor, Memantine, or antidepressant medication were required to have been on medication for a minimum period of 90 days before baseline. | Prior exposure to amyloid vaccines, monoclonal antibodies, or IV immunoglobulins for the treatment of AD\*. Also patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis, or those taking anti–TNF-α agents, immunosuppressive drugs, and/or oral prednisone>10 mg/d within the past 90 days. Also participants with known contraindications (active infections) or cautions (previous significant exposure to tuberculosis, herpes zoster, hepatitis B, heart failure, demyelination disorders, and active malignancy within past 5 years to the use of etanercept. |
| **Chou et al. (2016)** | A diagnosis of RA\* based on at least two outpatient claims with the same diagnosis or one inpatient claim as defined by ICD-9\* for RA and a new diagnosis of AD made at least 120 days after the initial diagnosis of RA | Identifiable diagnosis of RA prior to the analysis period, claims data about RA for 6 months prior to the analysis period. During any time of the analysis period, they also had a diagnosis of inflammatory bowel disease (Crohn’s disease and ulcerative colitis), psoriatic arthritis, frontotemporal dementia, Lewy body dementia, Parkinson’s disease, stroke, or vascular dementia, if they had a diagnosis of AD made before the index date (i.e., diagnosis of RA) or less than 120 days after the index date. If less than 12 months of data were available for assessment of exposure to different therapeutic agents after the index date |
| **Tobinick et al. (2006)** | Patients with a clinical diagnosis of AD declining despite the clinical treatment | Active infection, multiple sclerosis (or any other demyelinating disorder), vascular dementia, clinically significant neurologic disease other than AD or a score greater than 4 on the modified Hachinski Ischemic Rating Scale, pregnancy, uncontrolled diabetes mellitus, tuberculosis, history of lymphoma, or congestive heart failure. Female participants who were premenopausal, fertile, or not on acceptable birth control; and patients with a white blood cell count < 2500 cells/mm3, hematocrit < 30, or a platelet count < 100,000 cells/mm3. Study eligibility also required the dose of all central nervous system-active medications to be unchanged in the 4 weeks before study initiation and during the entire course of the clinical trial. |

Note: AD=Alzheimer’s Disease, ICD-9= The International Classification of Diseases, MMSE=The Mini–Mental State Examination; Ninth Revision; RA=rheumatoid arthritis TNF-α=Tumour Necrosis Factor- α;

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Random allocation of treatment** | **Blinding** | **Inclusion and exclusion criteria stated** | **Sample size calculation** | **Compliance with animal welfare requirements** | **Conflict of interest disclosed** | **Statistical model explained** | **Animals with comorbidity** | **Test animal details** | **Dose-response model** | **Every animal accounted for** | **Optimal time window used** |
| **Cavanagh et al. (2016)** | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Adequate | Adequate | Partially adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **Detrait et al. (2014)** | Adequate | Adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate | Adequate | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **Gabbita et al. (2012)** | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **He et al.** | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **Kim et al.** | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **McAlpine et al. (2009)** | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **Medeiros et al.** | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **Medeiros et al 2010.** | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **Montgomery et al. (2011)** | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **Roerink et al. (2015)** | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Adequate | Adequate | Inadequate/ unreported | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Partially adequate | Adequate |
| **Russo et al. (2012)** | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |
| **Shi et al. (2011)** | Adequate | Adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate | Adequate | Partially adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported |
| **Tweedie et al. (2012)** | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Inadequate/ unreported | Adequate | Inadequate/ unreported | Adequate | Inadequate/ unreported | Partially adequate | Inadequate/ unreported | Inadequate/ unreported | Adequate |

**Appendix D:** Methodological quality of animal studies.

**Appendix E:** Methodological quality of human studies.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Selection bias** | **Study design** | **Confounder** | **Blinding** | **Data collection methods** | **Withdrawals and drop-outs** | **Intervention integrity** |
| **Butchart et al. (2015)** | Adequate | Adequate | Adequate | Adequate | Adequate | Adequate | Partially Adequate |
| **Reason** | 1. Individuals somewhat likely to be representative of the target population 2. 80-100% of selected individuals agreed to participate | 1. Study design: RCT  2. Study randomised  3. Method of randomisation described  4. Method of randomisation was appropriate | 1. There were no important inter-group differences prior to the intervention  2. | 1. Outcome assessor unaware of the intervention or exposure status of participants 2. Participants unaware of the research question | 1. Data collection tools were valid 2. No information regarding the reliability of data collection tools | 1. Withdrawals and drop-outs were reported in terms of numbers and/or reasons per group 2. 80-100% of participants completed the study | 1. 80-100% of participants received the allocated intervention or exposure of interest 2 Consistency of intervention was not measured 3. Unlikely that subjects received an unintended intervention |
| **Chou et al. (2016)** | Partially Adequate | Partially Adequate | Inadequate or unclear | Partially Adequate | Adequate | Partially Adequate | Adequate |
| **Reason** | 1. Individuals somewhat likely to be representative of the target population  2. Retrospective study | 1. Study design: case- control  2. Study not randomised | 1. No information regarding inter-group differences 2. No information regarding the control of relevant confounders | 1. No information regarding the assessors 2. Participants unaware of the research question | 1. Data collection methods were valid 2. Data collection methods were reliable | Cannot comment on withdrawals and drop-outs due to the retrospective nature of the study |  |
| **Tobinick et al. (2006)** | Partially Adequate | Adequate | Inadequate or unclear | Partially adequate | Adequate | Adequate | Inadequate or unclear |
| **Reason** | 1. Individuals somewhat likely to be representative of the target population  2.. 80-100% of selected individuals agreed to participate | 1.Study design: controlled clinical trial 2. Study not randomised | 1. No information regarding inter-group differences 2. No information regarding the control of relevant confounders | 1. Outcome assessor unaware of the intervention or exposure status of participants 2. No information regarding the extent of information given to study participants | 1. Data collection methods were valid 2. Data collection methods were reliable | 1. Withdrawals and drop-outs were reported in terms of numbers and/or reasons per group 2. 80-100% of participants completed the study | 1. 80-100% of participants received the allocated intervention or exposure of interest 2 Consistency of intervention was not measured 3. No information regarding the possibility of unintended interventions |

**Appendix F:** Outcomes of animal studies.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Cognition and behavior** | **Reduction in brain tissue mass (atrophy)** | **Presence of tangles and plaques** | **Synaptic Function** | | **Other findings** | |
| **Cavanagh et al. (2016)** | Increase in latency in all XPro1595-treated mice (p<0.001). A significantly lower latency than untreated mice at day 8 (p<0.05) Decreased time spent in the avoidance task in either genotype, following treatment (p<0.05) | unreported | unreported | Treatment with XPro1595 caused a significantly greater decrease in mean fEPSP slope in slices from TgCRND8 mice (p<0.001).  XPro1595 (p< 0.01) abolished the increased LTP in slices from TgCRND8 mice. The input-output function in 6-month old TgCRND8 XPro1595-treated mice at a prodromal age was significantly higher than saline-treated TgCRND8 mice (p < 0.05) for the same fiber volley sizes and not significantly different than NTG controls | unreported | |
| **Detrait et al. (2014)** | Administration of the TNFR2:Fc counteracted amyloid-induced decrease in alternation percentage (p<0.01) Method of assessment: inhibitory avoidance Treatment with TNFR2:Fc increased the retention latencies in a dose-dependent manner. At 10mg/kg the retention latency was increased when compared with the control group. At 30mg/kg a complete reversal of the deficit was observed | unreported | unreported | unreported | | Hippocampal TNF-alpha levels doubled in mice administered with Aβ only (p<0.001). Treatment with TNFR2:Fc normalized the levels | |
| **Gabbita et al. (2012)** | 3,6′-dithiothalidomide prevents cognitive impairment (p<0.05) | unreported | No difference in the number of 6E10+ positive cells between the treated and control groups was found | unreported | | Both Thalidomide and 3,6′-dithiothalidomide significantly inhibited BV2 TNFα production p<0.0001 and reduced LPS-induced brain cortical TNFα mRNA and protein levels to near control values p<.0001 3,6′-dithiothalidomide treatment reduces brain and spleen tumor necrosis factor-α levels, p<.05 3,6′-DT reduces TNF-α in central nervous system-infiltrating leukocytes, p<.001 3,6′-dithiothalidomide decreased TNF-α in myelomonocytic/granulocytic cells, p=.0309 | |
| **He et al. (2013)** | unreported | unreported | Thalidomide reduced Aβ load (p<.05) Significant decrease in 6E10-positive plaques in the neocortex and hippocampus following thalidomide administration (p<0.01) In the Thalidomide-treated group the levels of insoluble Aβ1-42 and Aβ1-40 were reduced by 51% and 83%, respectively | unreported | | Significant decrease in BACE1 amount with thalidomide application (p<0.05), and lower BACE1 activity (p<0.05) No significant changes of APH-1 levels, nicastrin and PS-1 with thalidomide application (p>0.05) No significant changes in the amount of NEP and ODEA expression (p>0.05) | |
| **Kim et al. (2016)** | Infliximab treatment blocked Aβ1–42-induced impairment of recognition memory without affecting normal recognition memory (p=0.0113). Discrimination ratio was also restored after infliximab (p=0.0014) | unreported | unreported | ex vivo: Infliximab treatment blocked Aβ1–42-induced LTD impairment (P< 0.0001) without affecting control LTD (P = 0.0004) in vitro: Infliximab treatment blocked Aβ1–42-induced LTD impairment (P=0.0020) without affecting control LTD (P = 0.0092) | | unreported | |
| **McAlpine et al. (2009)** | unreported | unreported | lenti-DN-TNF-transduced brains displayed a significant (∼60%) reduction in accumulation of intraneuronal APP-derived 6E10-immunoreactive protein compared to lenti-GFP transduced (p<.05) XENP345 inhibited the appearance of 6E10-positive cells in the hippocampus (p<.05) Counts in the hilar region of the hippocampus revealed that administration of XENP345 significantly reduced the appearance of 6E10-IR protein in the hilar regions of the hippocampus of the LPS-treated 3xTgAD mice compared to the saline-infused animals (p<0.05) Inhibition of TNF signaling with the DN-TNF inhibitor XENP345 (p=0.34) or with lenti-DN-TNF (p=0.15) had no effect on levels of Aβ peptides | unreported | | unreported | |
| **Medeiros et al. (2007)** | iNOS inhibitor AG improved the cognitive deficits during training trials, p<.0001 and test trials p<.0001 on the Morris water maze | unreported | unreported | Prevented the synaptic disruption in the CA1, p<.01, CA2 p<.01 but not in the CA3 p<.05 and parietal cortex (p>.08) | | unreported | |
| **Medeiros et al. (2010)** | Treatment with NS398 resulted in a significant improvement of spatial learning deficits (p<0.05 and p<0.01 compared with the PBS/vehicle treated group, p<0.05 and p<0.01 compared with the AB1-50 vehicle treated group | unreported | unreported | unreported | | unreported | |
| **Montgomery et al. (2011)** | unreported | unreported | unreported | 3xTg-ADxTNF-RI/RII KO mice showed significantly smaller evoked fEPSPs compared with Non-Tg mice (p= 0.02) | | unreported | |
| **Roerink et al. (2015)** | unreported | unreported | unreported | unreported | | Perispinal injection of radioactively labelled cetuximab, etanercept and anakira resulted in the accumulation of the drugs in the brain in only one out of nine animals. In that animal, the concentration of the drug was less than 0.01% of the injected dose | |
| **Russo et al. (2012)** | Aβ1-42-induced memory deficits are abolished by 3,6′-dithiothalidomide treatment, p <.05 | unreported | 3,6′-dithiothalidomide treatment attenuates the effect of Aβ1-42 injection on hippocampal progenitor cell proliferation p<.01 3,6′-DT treatment diminishes the effect of Aβ1-42 –induced inflammation on BrdU-cells survival at 4 weeks, p<.001 | unreported | | 3,6′-dithiothalidomide treatment decreases microglia activation in response to Aβ1-42 – induced neuroinflammation p<.001 | |
| **Shi et al. (2011)** | unreported | unreported | Treatment with Infliximab resulted in a decreased in the amyloid plaques of APP/PS1 transgenic mice. A reduction in tau phosphorylation levels was also reported on semi-quantitative examination | unreported | | unreported | |
| **Tweedie et al. (2012)** | drug-treated animals performed at a level similar to control mice in the Morris Water (p<0.05) | unreported | unreported | unreported | | 3,6′-DT reduced LPS-induced chronic neuroinflammation and restores LPS-mediated abnormal hippocampal neuronal plasticity (p<0.05) | |

Note: Aβ= amyloid beta; APH-1=anterior pharynx-defective 1; APP= Amyloid Precursor; BACE1= Beta-secretase 1; DN-TNF= dominant negative tumor necrosis factor; fEPSP=field excitatory postsynaptic potential; GFP= green fluorescent protein; iNOS= Inducible nitric oxide synthase; LTD= Long-term depression; Protein; LPS= lipopolysaccharide; NEP= neutral endopeptidase; NTG= nontransgenic; PS-1= presenilin-1;TNFR2:Fc= tumor necrosis factor receptor 2 fused to a Fc domain (TNFR2:Fc); TNF-RI/RII KO= tumor necrosis factor receptor-1 knockout,

**Appendix G:** Outcomes of human studies.

|  |  |  |
| --- | --- | --- |
|  | **Cognition and Behaviour** | **Other statistically significant findings** |
| **Butchart et al. (2015)** | **Observed Cases** Week 12:  no significant difference between etanercept and placebo on SMMSE (p=1.0), ADAS-cog (p=0.9), BADLS (p=0.8), NPI (p=0.2), CSDD (p=0.9), CGI-I (p=0.6) Week 24 no significant differences on ADAS-cog (p=0.7), CSDD (p=0.4), SMMSE (p=0.07) or CGI-I (p=0.3) were seen, but a significant difference on BADLS (p=0.04) and NPI (p=0.02) **ITT-LOCF** Week 12 no significant difference between the etanercept and placebo groups on SMMSE (p=0.9), ADAS-cog (p=0.8), BADLS (p=0.8), NPI (p=0.2), CSDD (p=0.9), CGI-I (p=0.7) Week 24 no significant difference on SMMSE (p=0.2), ADAS-cog (p=0.5), BADLS (p=0.1), NPI (p=0.2), CSDD (p=0.6), CGI-I (p=0.8) |  |
| **Chou et al. (2016)** |  | Only the anti-TNF agents as a group showed a significant reduction in the relative risk of AD among RA subjects following treatment (p=0.02)  A significant decrease in the relative risk of AD in RA subjects following treatment was only found in the Etanercept group (p=0.03) |
| **Tobinick et al. (2006)** | A significant beneficial effect of treatment on the change in MMSE (p<0.001), ADAS-Cog (p<0.002), and SIB (p<0.001) from baseline |  |

Note: AD= Alzheimer’s Disease; ADAS-cog= Alzheimer's Disease Assessment Scale-cognitive subscale; BADLS= The Bristol Activities of Daily Living Scale; CGI= The Clinical Global Impressions Scale; (CSDD)=The Cornell Scale for Depression in Dementia; ITT-LOCF= Intent-to-Treat Last Observation Carried Forward; SMMSE= Standardized Mini-Mental State Examination; NPI= The Neuropsychiatric Inventory